{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:29:36Z","timestamp":1784366976953,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231039"],"award-info":[{"award-number":["K20231039"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008109","name":"Wuxi Municipal Bureau on Science and Technology","doi-asserted-by":"publisher","award":["K20231049"],"award-info":[{"award-number":["K20231049"]}],"id":[{"id":"10.13039\/501100008109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104244"],"award-info":[{"award-number":["82104244"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jad.2025.04.091","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:25:14Z","timestamp":1745029514000},"page":"186-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database"],"prefix":"10.1016","volume":"382","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.04.091_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12884-021-04016-9","article-title":"Prevalence and risk factors of postpartum depression in the Middle East: a systematic review and meta\u2013analysis[J]","volume":"21","author":"Alshikh Ahmad","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.jad.2025.04.091_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2025.04.091_bb0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"issue":"2","key":"10.1016\/j.jad.2025.04.091_bb0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.64719\/pb.4397","article-title":"Brexanolone to treat postpartum depression in adult women[J]","volume":"51","author":"Cornett","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"3","key":"10.1016\/j.jad.2025.04.091_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"key":"10.1016\/j.jad.2025.04.091_bb0030","article-title":"Brexanolone, a GABAA modulator, in the treatment of postpartum depression in adults: a comprehensive review[J]","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psychol."},{"issue":"6","key":"10.1016\/j.jad.2025.04.091_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jad.2025.04.091_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320968658","article-title":"Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?[J]","volume":"10","author":"Faden","year":"2020","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12035-023-03574-7","article-title":"The role of Extrasynaptic GABA receptors in postpartum depression[J]","volume":"61","author":"Feng","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.jad.2025.04.091_bb0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40801-023-00372-4","article-title":"Safety of brexanolone in adults with postpartum depression: postmarketing surveillance data[J]","volume":"10","author":"Garafola","year":"2023","journal-title":"Drugs-Real World Outcomes"},{"key":"10.1016\/j.jad.2025.04.091_bb0055","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jad.2024.07.103","article-title":"Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database[J]","volume":"362","author":"Gu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2025.04.091_bb0060","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1038\/s41380-023-02193-x","article-title":"Brain-wide changes in excitation-inhibition balance of major depressive disorder: a systematic review of topographic patterns of GABA-and glutamatergic alterations[J]","volume":"28","author":"Hu","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.04.091_bb0065","first-page":"1","article-title":"The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database[J]","author":"Jiang","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0070","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41598-024-58460-6","article-title":"Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0075","article-title":"Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database[J]","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12888-024-05813-0","article-title":"Exploring adverse events of Vilazodone: evidence from the FAERS database[J]","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.04.091_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database[J]","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.04.091_bb0090","first-page":"1","article-title":"Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects[J]","author":"Jin","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0095","first-page":"28","article-title":"Effects of transcranial magnetic stimulation combined with sertraline on cognitive level, inflammatory response and neurological function in depressive disorder patients with non-suicidal self-injury behavior[J]","volume":"52","author":"Liu","year":"2024","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.jad.2025.04.091_bb0100","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jad.2024.03.085","article-title":"Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database[J]","volume":"354","author":"Lu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jad.2025.04.091_bb0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/biom14040460","article-title":"Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors of the mouse nucleus accumbens[J]","volume":"14","author":"Mitchell","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaclp.2021.08.001","article-title":"A brexanolone treatment program at an academic medical center: patient selection, 90-day posttreatment outcomes, and lessons learned[J]","volume":"63","author":"Patterson","year":"2022","journal-title":"Journal of the Academy of Consultation-Liaison Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.04.091_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression[J]","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.scib.2021.09.007","article-title":"GABAA (\u03b4) receptor hypofunction in the amygdala-hippocampal circuit underlies stress-induced anxiety[J]","volume":"67","author":"Qin","year":"2022","journal-title":"Sci. Bull."},{"issue":"8","key":"10.1016\/j.jad.2025.04.091_bb0125","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.jad.2025.04.091_bb0130","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40262-022-01155-w","article-title":"Allopregnanolone concentrations in breast milk and plasma from healthy volunteers receiving brexanolone injection, with population pharmacokinetic modeling of potential relative infant dose[J]","volume":"61","author":"Wald","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jad.2025.04.091_bb0135","article-title":"A novel treatment of postpartum depression and review of literature[J]","volume":"14","author":"Yoon","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jad.2025.04.091_bb0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00737-023-01378-1","article-title":"Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS)[J]","volume":"27","author":"Zhang","year":"2024","journal-title":"Arch. Womens Ment. Health"},{"key":"10.1016\/j.jad.2025.04.091_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","article-title":"Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database[J]","volume":"347","author":"Zhu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2025.04.091_bb0150","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1007\/s12264-021-00689-6","article-title":"Hypothalamic-pituitary-end-organ axes: hormone function in female patients with major depressive disorder[J]","volume":"37","author":"Zhu","year":"2021","journal-title":"Neurosci. Bull."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725006652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:39:49Z","timestamp":1778243989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725006652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S0165032725006652"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.091","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.04.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}